



FAX RECEIVED

MAR 23 2001

GROUP 1600

TELEFAX TRANSMITTAL COVER SHEET

Date: 3/22/2001
Number of Pages: 15 (fifteen)
(Including Cover Sheet)

To: Michael Pak Company/Department: Art Unit: 1646 Fax Number: 703.308.4242

From: Michael G. Sullivan Company/Department: Patent Department Fax Number: (301) 948-9751
Rockville, Maryland (301) 948 - 7400

Subject/Reference: Moselman et al. 08/826,361

Remarks:

CONFIDENTIAL

Pls. accept the following:

- Amendment (pgs. 11)
- Version w/markings (pg. 2)
- Petition for Ext. of Time (pg. 1)

Thank you.

Warning: The information contained in this facsimile message is attorney privileged and confidential information intended only for use of the individual or entity named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is wrongful and may subject you to civil liability. If you have received this communication in error, please immediately notify us by telephone, and return the original message to us at 1300 Piccard Drive #206, Rockville, MD 20850 via the U.S. Postal Service. Thank you.

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

BY: John C. Pak
Date: 3/22/2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

MOSSELMAN ET AL.

Serial Number: 08/826,361 Group Art Unit: 1646

Filed: March 26, 1997 Examiner: M. Pak

For: NOVEL ESTROGEN RECEPTOR

AMENDMENTAssistant Commissioner of Patents
Washington, D.C. 20231

March 22, 2001

Sir:

In response to the Office Action dated November 22, 2000,
03/27/2001 GTRAMMEL 00000003 022334 08826361
01 FC:103 please enter the following replacement amendments and reconsider
72.00 CH
the pending rejections in view of the remarks below. A petition
for a one month extension of time accompanies this response.

IN THE CLAIMS:

Please cancel claim 19 without prejudice or disclaimer of
the subject matter thereof.

Please replace claims 1-3, 8 and 12 with the following:

1. (Twice amended) An isolated DNA encoding an isolated
human estrogen receptor protein having a DNA-binding domain and a
ligand-binding domain, wherein the amino acid sequence of said
DNA-binding domain exhibits at least 80% homology with the amino